All-Oral Regimens -- The Future of Hepatitis C Treatment


Attendees at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco got a glimpse of the future of chronic hepatitis C therapy, as several researchers presented data from studies of all-oral direct-acting antiviral (DAA) regimens -- without interferon and its notoriously difficult side effects.

NEJM: High SVR Rate with Daclatasvir + Asunaprevir

AASLD: Daclatasvir + Asunaprevir Suppresses HCV in Null Responders

AASLD: PSI-7977 + Ribavirin Cures Hepatitis C in 12 Weeks

AASLD: BI 201355 + BI 201127 + Ribavirin Looks Good in SOUND-C